Pharming Announces Positive Data from Phase II/III Leniolisib ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
LEIDEN, Netherlands, April 2, 2022 /PRNewswire-AsiaNet/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3K delta) syndrome (A...
Authors: LATEST ASIANET NEWS RELEASES